Our study establishes FCGR2A-mediated myeloid reprogramming as a critical interface between metabolic dysfunction and ccRCC progression, serving as both a prognostic biomarker and therapeutic target. This evidence concerns the gene FCGR2A and nonpapillary renal cell carcinoma.